This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Medco To Present Results Of National Study On Effect Of Genetic Testing On Patient Medication Adherence At The American College Of Cardiology 61st Annual Scientific Session And Expo

FRANKLIN LAKES, N.J., March 14, 2012 /PRNewswire/ -- The final results of the Additional KIF6 Risk Offers Better Adherence to Statins (AKROBATS) study will be presented at the American College of Cardiology's 61st Annual Scientific Session & Expo being held March 24-27, 2012, in Chicago, IL. The AKROBATS study is a collaborative effort between the Medco Research Institute™, a subsidiary of Medco Health Solutions, Inc. (NYSE: MHS) and Quest Diagnostics (NYSE: DGX), the world's leading diagnostic testing company.

(Logo: http://photos.prnewswire.com/prnh/20100609/MEDCOLOGO )

Presentation Details

Session Number: 1258

Session Type: ACC Moderated Poster Contributions

Session Start/End Time: Monday, Mar 26, 2012, 9:30 AM -10:30 AM

Location: McCormick Place South, Hall A

Presentation Number: 1258-376 

Abstract Title: Patient knowledge of pharmacogenetic information improves adherence to statin therapy: Results of the Additional KIF6 Risk Offers Better Adherence to Statins (AKROBATS) trial. 

Presenter:  Scott L. Charland, Pharm.D., Medco Research Institute

About AKROBATS

AKROBATS is prospective, nonrandomized intervention trial of the effect of KIF6 testing results reported directly to the patient on statin adherence and persistence over six months.  All eligible intervention and control patients were greater than or equal to 18 years old, new to statin therapy (none 6 months prior), and from the same sponsored plans (which had granted permission for their members to participate in the study). Genetic testing for a common single nucleotide polymorphism (rs20455) resulting in an arginine to tryptophan substitution at position 719 (Trp719Arg) in the kinesin-like protein 6 gene ( KIF6) was conducted and written results returned to the patient within 30 days of initiating statin therapy, and before the first statin prescription refill.  Tested patients were matched to concurrent, non-tested control patients on age, gender, statin prescription distribution channel, and the number of chronic medications at time of statin initiation. The primary endpoint was statin adherence (proportion of days covered; PDC) at six months.  Secondary end points included achievement of adherence (PDC greater than or equal to 0.80) and persistence to statin therapy at six months.  AKROBATS is registered on www.clinicaltrials.gov (NCT01068834).

About Medco Research Institute

Medco Research Institute® is an evidence-based research organization focused solely on novel research, analytics and new discoveries that close the gap between scientific discovery and medical practice for improved patient outcomes and lower overall healthcare costs. More information about the Medco Research Institute's peer-reviewed research can be found at www.medcoresearch.com.



1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,075.94 -22.51 -0.13%
S&P 500 2,002.27 -1.10 -0.05%
NASDAQ 4,590.2930 +10.0220 0.22%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs